Cover Image
市場調查報告書

B型肝炎:開發中產品分析

Hepatitis B - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 232823
出版日期 內容資訊 英文 386 Pages
訂單完成後即時交付
價格
Back to Top
B型肝炎:開發中產品分析 Hepatitis B - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 386 Pages
簡介

B型肝炎是危險到會威脅生命的肝臟感染症。B型肝炎病毒是造成黃膽、尿液暗沈、嚴重倦怠、噁心、嘔吐、伴隨腹痛的急性疾病的原因。B型肝炎致病風險因子有年齡、嚴重的腎臟病、血友病、重覆使用的注射針頭、由感染B型肝炎的母親所生下的嬰兒等。 可用抗病毒藥物等治療。

本報告提供B型肝炎治療藥的開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

B型肝炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

B型肝炎:企業開發中的治療藥

B型肝炎:大學/機關研究中的治療藥

B型肝炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

B型肝炎:企業開發中的產品

B型肝炎:大學/機關研究中的產品

B型肝炎的治療藥的開發企業

B型肝炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

B型肝炎:最近的開發平台趨勢

B型肝炎:暫停中的計劃

B型肝炎:中止開發的產品

B型肝炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7979IDB

Summary

Global Markets Direct's, 'Hepatitis B - Pipeline Review, H1 2016', provides an overview of the Hepatitis B pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatitis B
  • The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatitis B

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis B
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatitis B Overview
  • Therapeutics Development
  • Hepatitis B - Therapeutics under Development by Companies
  • Hepatitis B - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis B - Pipeline Products Glance
  • Hepatitis B - Products under Development by Companies
  • Hepatitis B - Products under Investigation by Universities/Institutes
  • Hepatitis B - Companies Involved in Therapeutics Development
  • Hepatitis B - Therapeutics Assessment
  • Drug Profiles
  • Hepatitis B - Recent Pipeline Updates
  • Hepatitis B - Dormant Projects
  • Hepatitis B - Discontinued Products
  • Hepatitis B - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hepatitis B, H1 2016
  • Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hepatitis B - Pipeline by Abivax S.A., H1 2016
  • Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H1 2016
  • Hepatitis B - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Hepatitis B - Pipeline by Akshaya Bio Inc., H1 2016
  • Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by AlphaMab Co., Ltd, H1 2016
  • Hepatitis B - Pipeline by Altimmune, Inc., H1 2016
  • Hepatitis B - Pipeline by Altravax, Inc., H1 2016
  • Hepatitis B - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Hepatitis B - Pipeline by Arbutus Biopharma Corporation, H1 2016
  • Hepatitis B - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Assembly Biosciences, Inc., H1 2016
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Hepatitis B - Pipeline by Benitec Biopharma Limited, H1 2016
  • Hepatitis B - Pipeline by BioDiem Ltd, H1 2016
  • Hepatitis B - Pipeline by Biogenomics Limited, H1 2016
  • Hepatitis B - Pipeline by Biological E. Limited, H1 2016
  • Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H1 2016
  • Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by CaroGen Corporation, H1 2016
  • Hepatitis B - Pipeline by Celltrion, Inc., H1 2016
  • Hepatitis B - Pipeline by Chimerix, Inc., H1 2016
  • Hepatitis B - Pipeline by ChronTech Pharma AB, H1 2016
  • Hepatitis B - Pipeline by Cocrystal Pharma, Inc., H1 2016
  • Hepatitis B - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by CyTuVax B.V., H1 2016
  • Hepatitis B - Pipeline by Dynavax Technologies Corporation, H1 2016
  • Hepatitis B - Pipeline by Ensemble Therapeutics Corporation, H1 2016
  • Hepatitis B - Pipeline by Enyo Pharma S.A.S., H1 2016
  • Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H1 2016
  • Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Hepatitis B - Pipeline by GeneCure LLC, H1 2016
  • Hepatitis B - Pipeline by Gilead Sciences, Inc., H1 2016
  • Hepatitis B - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Hepatitis B - Pipeline by Green Cross Corporation, H1 2016
  • Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by Humabs BioMed SA, H1 2016
  • Hepatitis B - Pipeline by Immunotope, Inc., H1 2016
  • Hepatitis B - Pipeline by Immunovaccine, Inc., H1 2016
  • Hepatitis B - Pipeline by Indian Immunologicals Limited, H1 2016
  • Hepatitis B - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by ISA Pharmaceuticals B.V., H1 2016
  • Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by Johnson & Johnson, H1 2016
  • Hepatitis B - Pipeline by Kineta, Inc., H1 2016
  • Hepatitis B - Pipeline by Kuros Biosciences AG, H1 2016
  • Hepatitis B - Pipeline by Leukocare AG, H1 2016
  • Hepatitis B - Pipeline by LG Life Science LTD., H1 2016
  • Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Mologen AG, H1 2016
  • Hepatitis B - Pipeline by Mucosis B.V., H1 2016
  • Hepatitis B - Pipeline by MultiCell Technologies, Inc., H1 2016
  • Hepatitis B - Pipeline by Panacea Biotec Limited, H1 2016
  • Hepatitis B - Pipeline by Pfenex Inc., H1 2016
  • Hepatitis B - Pipeline by PharmaEssentia Corporation, H1 2016
  • Hepatitis B - Pipeline by Profectus BioSciences, Inc., H1 2016
  • Hepatitis B - Pipeline by Redx Pharma Plc, H1 2016
  • Hepatitis B - Pipeline by REPLICor Inc., H1 2016
  • Hepatitis B - Pipeline by Sanofi Pasteur SA, H1 2016
  • Hepatitis B - Pipeline by SEEK Group, H1 2016
  • Hepatitis B - Pipeline by Sinovac Biotech Ltd., H1 2016
  • Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by TCM Biotech International Corp, H1 2016
  • Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Hepatitis B - Pipeline by TGV-Laboratories, H1 2016
  • Hepatitis B - Pipeline by Theravectys SA, H1 2016
  • Hepatitis B - Pipeline by Tomegavax, Inc., H1 2016
  • Hepatitis B - Pipeline by Transgene SA, H1 2016
  • Hepatitis B - Pipeline by UAB Profarma, H1 2016
  • Hepatitis B - Pipeline by Vaxine Pty Ltd, H1 2016
  • Hepatitis B - Pipeline by Viriom Ltd., H1 2016
  • Hepatitis B - Pipeline by VLP Biotech, Inc., H1 2016
  • Hepatitis B - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hepatitis B Therapeutics - Recent Pipeline Updates, H1 2016
  • Hepatitis B - Dormant Projects, H1 2016
  • Hepatitis B - Dormant Projects (Contd..1), H1 2016
  • Hepatitis B - Dormant Projects (Contd..2), H1 2016
  • Hepatitis B - Dormant Projects (Contd..3), H1 2016
  • Hepatitis B - Dormant Projects (Contd..4), H1 2016
  • Hepatitis B - Dormant Projects (Contd..5), H1 2016
  • Hepatitis B - Dormant Projects (Contd..6), H1 2016
  • Hepatitis B - Dormant Projects (Contd..7), H1 2016
  • Hepatitis B - Dormant Projects (Contd..8), H1 2016
  • Hepatitis B - Dormant Projects (Contd..9), H1 2016
  • Hepatitis B - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hepatitis B, H1 2016
  • Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top